Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2007
09/13/2007US20070213297 Arrays with cleavable linkers
09/13/2007US20070213296 Compositions and methods for the treatment of immunoinflammatory disorders
09/13/2007US20070213295 Methods and compositions for inducing torpor in a subject
09/13/2007US20070213294 Methods for modulating the axonal growth of central nervous system neurons
09/13/2007US20070213291 Therapeutically useful synthetic oligonucleotides
09/13/2007US20070213290 Neurite regeneration
09/13/2007US20070213288 Adenoviral Vector Capable of Infecting Tumor Cells and Eliminating the Function of STAT3
09/13/2007US20070213287 Introducing nucleic acid encoding therapeutic gene product formulated with an anionic polymer selected from polyglutamic acid, polyaspartic acid, polygalacturonic acid, poly vinyl sulfate into cell
09/13/2007US20070213285 Methods and compositions for cancer therapy
09/13/2007US20070213284 Method of selecting targets for gene silencing by RNA interference
09/13/2007US20070213283 Macrolides substituted at the 4"-position
09/13/2007US20070213282 Peroxisome proliferator-activated receptor (PPAR) activator, and drugs, supplements, functional foods and food additives using the same
09/13/2007US20070213281 Analogues of Oroxylin-A, Chrysin and Baicalein as antiulcer agents and mucoprotective agents from a new source new source Oroxylum indicum dried stem bark; flavanoids; gastrointestinal disorders; peptic ulcers; side effect reduction
09/13/2007US20070213280 Steroidal Saponins Compound, the Process for Producing the Same and the Use Thereof
09/13/2007US20070213279 O6-alkylguanine-dna alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
09/13/2007US20070213278 Arrays with cleavable linkers
09/13/2007US20070213277 Compositions and methods for enhancing drug delivery across and into ocular tissues
09/13/2007US20070213275 Formulations for ecallantide
09/13/2007US20070213271 Composition and method for treating hiv infection
09/13/2007US20070213270 Peptide yy formulations having increased stability and resistance to microbial agents
09/13/2007US20070213268 inhibiting angiogenesis in tissues expressing a endocrine gland-derived vascular endothelial growth factor(EG-VEGF) polypeptide, comprising contacting the tissue with an antagonist antibody of the EG-VEGF polypeptide or an antigen binding fragment; regulating cellular proliferation and chemotaxis
09/13/2007US20070213261 Asthma Preparation
09/13/2007US20070213259 Method for stabilizing blood pressure in hemodialysis subjects
09/13/2007US20070213256 Novel genes and proteins encoded thereby
09/13/2007US20070212769 Transfection, culturing; electrophoresis
09/13/2007US20070212758 Methods for the production of 3-o-deactivated-4'-monophosphoryl lipid a (3d-mla)
09/13/2007US20070212756 Methods for treating lentivirus infections
09/13/2007US20070212714 Novel genes TZap7/A, TZap7/B and TZap7 involved in T cell activation and uses thereof
09/13/2007US20070212431 Cream for treatment of skin injured by the sun
09/13/2007US20070212430 Method for weight reduction
09/13/2007US20070212429 Compositions and methods for increasing adipose metabolism, lipolysis or lipolytic metabolism via thermogenesis
09/13/2007US20070212428 Methods and compositions for treating mood disorder
09/13/2007US20070212427 Hormone replacement formulation
09/13/2007US20070212426 Composition and method of retarding viral activity and reducing viral replication
09/13/2007US20070212421 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
09/13/2007US20070212419 Synthesis of biocompatible nanocomposite hydrogels as a local drug delivery system
09/13/2007US20070212417 Compressible resilient granules and formulations prepared therefrom
09/13/2007US20070212416 Controlled Release Matrix Pharmaceutical Dosage Formulation
09/13/2007US20070212415 Sustained-release tablet containing doxazosin mesylate
09/13/2007US20070212414 Ethanol-resistant sustained release formulations
09/13/2007US20070212413 Sustained-release oral molsidomine composition for treating atherosclerosis
09/13/2007US20070212412 Stable solid formulation of sertindole
09/13/2007US20070212409 Stable pharmaceutical compositions for 2-aza-bicyclo [3.30]-octane-3-carboxylic acid derivatives
09/13/2007US20070212408 Stable Pharmaceutical Composition Containing Benzimidazole Derivatives and Method of Manufacturing the Same
09/13/2007US20070212406 Homeopathic drug composition and methods of use thereof
09/13/2007US20070212402 Patch
09/13/2007US20070212395 Ocular therapy using sirtuin-activating agents
09/13/2007US20070212394 Taxane coatings for implantable medical devices
09/13/2007US20070212393 Compositions and coatings for implantable medical devices
09/13/2007US20070212392 Chemoprevention of endometrial cancer
09/13/2007US20070212391 Stabilised prostaglandin composition
09/13/2007US20070212385 Fluidic Tissue Augmentation Compositions and Methods
09/13/2007US20070212380 Conjugated Fatty Acid Based Emulsion and Methods for Preparing and Using Same
09/13/2007US20070212371 Processes for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants
09/13/2007US20070212370 Soluble CD83 proteins and use thereof for the treatment and prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
09/13/2007US20070212368 Proteins
09/13/2007US20070212366 Use Of Mrp4-Inhibitors For The Treatment And/Or Prophylaxis Of Cardiovascular Diseases
09/13/2007US20070212363 Immunoglobulins with Potent and Broad Antiviral Activity
09/13/2007US20070212360 Modulation of mitochondrial oxygen consumption for therapeutic purposes
09/13/2007US20070212358 Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
09/13/2007US20070212352 Methods and compositions for the treatment of polycystic diseases
09/13/2007US20070212351 Novel therapeutic targets in cancer
09/13/2007US20070212348 Compositions and methods for the treatment and prevention of cancer, angiogenesis, and inflammation
09/13/2007US20070212347 Compositions and methods for treating polycystic kidney disease gene
09/13/2007US20070212346 Highly Concentrated Stabilized Igm Solution
09/13/2007US20070212345 Methods And Compositions For The Prevention And Treatment Of Gentiourinary Disorders Including Pre-Term Labor And Leiomyomas
09/13/2007US20070212344 Pharmaceutical preparation with RNA as hemostasis cofactor
09/13/2007US20070212343 Compositions for treatment of ear infections
09/13/2007US20070212339 Use Of At Least One Effector Of Glutathione Metabolism Together With Alpha-Lipoic Acid For The Treatment Of Chronically Obstructive Lung Diseases
09/13/2007US20070212334 Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
09/13/2007US20070212329 Vaccine Compositions Comprising An Interleukin 18 And Saponin Adjuvant System
09/13/2007US20070212327 Allergen Depressant And Depression Method
09/13/2007US20070212326 Polyquaternary organosilicon compounds-containing composition
09/13/2007US20070212325 Insulin Resistance-Improving Agent
09/13/2007US20070212322 cationic addition copolymers, use for hair, skin; polyTMAEAMS (methylsulfate[2-(acryloyloxy)ethyl]-trimethylammonium) first block (Mw=11,000 g/mole) and a polyacrylamide
09/13/2007US20070212307 Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
09/13/2007US20070212302 Preparation and Use of a Stable Formulation of Allosteric Effector Compounds
09/13/2007US20070212300 Delivery of compounds with rehydrated blood cells
09/13/2007US20070209660 Intranasal Opioid Compositions, Delivery Devices and Methods of Using Same
09/13/2007DE202006014513U1 Pharmazeutische Zusammensetzung, insbesondere Antazidum A pharmaceutical composition, in particular antacid
09/13/2007DE19981169B4 Kovalent an Gallensäuren oder Sterine gebundenes Heparin, dessen Verwendung und diese enthaltende pharmazeutische Zusammensetzung Covalently bound to bile acids or sterols heparin, its use and these pharmaceutical composition containing
09/13/2007DE19901270B4 Verfahren zur Flüssigkultivierung von Schizophyllum commune Fr. zur Isolierung von β-1,6-verzweigtem-β-1,3-Glucan Process for the liquid cultivation of Schizophyllum commune Fr. for the isolation of β-1,6-branched-β-1,3-glucan
09/13/2007DE102006042615A1 Sicherung der Stabilität von Phytomenadion-haltigen flüssigen Arzneimittelzubereitungen zum Einnehmen mittels Zusatz von 0,01% Natriumedetat Ensuring the stability of phytomenadione-containing liquid pharmaceutical preparations for internal use by the addition of 0.01% sodium edetate
09/13/2007DE102006011012A1 Verwendung von Zinkcysteinat zur Behandlung von Entzündungen oder Allergien der Atemwege Using Zinkcysteinat for treating inflammation or respiratory allergies
09/13/2007DE102006010643A1 Using quaternary ammonium compounds to inhibit precipitation of fluoroquinolone antibiotics, particularly in ready-for-use formulations for veterinary medicine
09/13/2007DE102006010329A1 Hormonelles Kontrazeptivum auf der Basis eines Estrogens, eines Gestagens oder einer Kombination von Estrogenen und Gestagenen unter der Zugabe von Testosteron Hormonal contraceptive on the basis of an estrogen, a progestogen or a combination of estrogens and progestins with the addition of testosterone
09/13/2007DE102004028241B4 Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel New fluoroglycoside derivatives of pyrazoles, pharmaceutical compositions containing them and Manufacturing of these products
09/13/2007CA2657606A1 Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries
09/13/2007CA2651943A1 Antiviral drugs for treatment of arenavirus infection
09/13/2007CA2646884A1 The use of bupropion metabolites for the treatment of inflammatory disorders
09/13/2007CA2646883A1 The use of beta-aminoalcohols for the treatment of inflammatory disorders and pain
09/13/2007CA2646882A1 The use of beta-aminoalcohols in the treatment of inflammatory disorders and pain
09/13/2007CA2646429A1 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
09/13/2007CA2646409A1 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
09/13/2007CA2645719A1 Compounds that modulate ppar activity, their preparation and use
09/13/2007CA2645684A1 Compositions and methods of use of ritonavir for treating hcv
09/13/2007CA2645320A1 Hormone replacement formulation
09/13/2007CA2645318A1 Pharmaceutical formulations containing metformin
09/13/2007CA2645227A1 Hydrazido derivatives of hyaluronic acid
09/13/2007CA2645211A1 Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases